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I ABSTRACT
Modulation of kidney cyclic AMP pdase by diuretics
and antihypertensives was studied. It was found that
spironolactone activates pdase and that furosemide,
ethacrynic acid, triameterine , quinethazone, metolazone,
chlorothiazide, propranolol and hydralazine, inhibit
pdase. The relative tissue specificity (medulla or
cortex) for some of the compounds appears to be in
agreement with the proposed sites of drug action via
pharmocological mechanisms which do not involve Inter
action with cAMP pdase .
The specific activity of pdase in the medulla was
found to be double that in the cortex. Pdase was found




Experiments were performed to study the effects of




(EC-3 .1.4.c) (cAMP) from homogenates of kidney medulla
and cortex of Sprague-Dawley rats and from genetically
similar normotensive (NH) and spontaneously hypertensive
rats (SH) .
The introduction will discuss: a) cAMP metabolism
and function particularly in the kidney; b) kidney struc
ture and function; c) the therapeutic roles and proposed
physiological sites of action of diuretics and antihyper
tensive agents; d) spontaneous hypertension; and e) the
characteristics of cyclic AMP pdase.
B. Cyclic AMP




-cyclic monophosphate, cAMP ,













triphosphate; DOPA, dihydroxyphenylalanine; EGME, ethylene
glycol monomethyl ether; EH, essential hypertension; cGMP
guanosine-3'
-cyclic monophosphate; NH, normotensive
or nonhypertensive ; pdase, phosphodiesterase; SH, spon
taneously hypertensive; TSH, thyroid stimulating hormone.
is a white crystalline solid with a molecular v/eight of
3292, soluble in water at alkaline pH and stable frozen.
It has a >* max of 259 nm at pH 7 with a molar absorptivity
of 15,300 and a a
h'
of hydrolysis for the
3'
-phosphodiester
bond of -14 Kcal/mole.
2. Metaboliam of Cyclic AMP
Rail and Sutherland (1957) found that cAMP is enzyma-
tically formed from ATP by:
ATP
adenyl
cyclase> cAMp + pyr0phosphate.




cAMP + H20 Phosphodiesterase^ ^^
The further catabolism of
5'
-AMP is shown in figure 1.














































Cyclic AMP was discovered by Sutherland (1957) during
investigations of the mechanism of the hyperglycemic
action of epinephrine and glucagon in liver- He sub
sequently found cAMP in all mammalian tissues that were
examined .
Sutherland (1958) called cAMP a "secondary hormone".
Some hormones stimulate the formation of cAMP from ATP
by activating adenyl cyclase in cell membranes . Intra
cellular liver elevations of cAMP activate protein
kinases which begin a cascade of reactions leading to
the release of glucose from glycogen.
Several reviews about cAMP (Robison et- al. , 1968;
Jost and Rickenburg, 1971; Pastan et al. , 1975) are
briefly summarized below. Cyclic AMP has been found to
mediate the action of many hormones e.g. : melanocyte
stimulating hormone, parathyroid hormone,
adrenocortico-
trophic hormone, norepinephrine, thyroid stimulating
hormone, vasopressin, luteinizing hormone, and sex hor
mones. Cyclic AMP has been demonstrated to directly or
indirectly effect the activity of many enzymes, e.g.
phosphorylase, phosphofructokinase, pyruvate kinase,
tyrosine aminotransferase , glycogen synthetase and
fructose-1, 6-diphosphatase. Cyclic AMP stimulates
lipolysis, steroidogenesis, urea formation, ketogenesis,
the release of salivary amylase, hydrochloric acid
secretion in the stomach and transcription of genes for
inducible enzymes. Cyclic AMP decreases the rate of
formation of liver protein from amino acids, cell pro
liferation, translation of messenger RNA, and the forma
tion of liver fatty acids. Cyclic AMP also is necessary
for retinal photoreception responses (its level rises),
nerve impulse transmission, and morphogenesis (at least
in lower organisms such as Dictyostelium)- Cyclic AMP




Rat kidneys are located behind the parietal peri
toneum in the abdominal cavity. At the hilus blood enters
the kidney through the renal artery and leaves through
the renal vein and urine leaves through the ureter. The
kidney consists of four basic sections : the thin outer
membrane, the cortex, the medulla and the papillae, figure
2. The renal artery branches many times to form about
one half million networks of capillaries called glomeruli .
The capillaries of a single glomerulus rejoin to form
the efferent arteriole. The efferent arteriole then splits
and part of it forms the capillary network which surrounds
each individual renal tubule . The network then reunites
and joins the remainder of the efferent arteriole. The
efferent arterioles finally unite to form the renal vein,











Figure 2 . Longitudinal Section of Human Kidney
(Grollman, 1970).
Figure 3a. Juxtamedullary Nephron-Anatomy (Kory, 1969)
Key ^ ^ blood flow
> ' ' ' > tubular fluid flow
Figure 3h. Juxtamedullary Nephron-Psysiology (Kory, 1969)
(the space into which the blood is filtered from a glom
erulus), continues to the proximal convuluted tubule,
loop of Henle, distal tubule and collecting duct. The
collecting ducts join in a cavity called the calyx or
pelvis. The ureter leads from the calyx to the bladder.
2. Functions, of the Kidney
Four basic functions of the kidney are: a) excretion
of metabolic wastes and, maintenance of the physiological
balances of blood plasma, b) water, c) electrolytes, and
d) pH.
Blood is filtered through the glomeruli at about
125 ml/min. The blood cells and large molecules pass
on toward the renal vein through the efferent arterioles.
The cell free filtrate enters Bowman's capsule which is
the beginning of a tubule. In the proximal tubule, salts,
amino acids, glucose, hormones, vitamins and small proteins
are returned to the efferent arterioles through active
or passive transport across the tubular membrane. Approx
imately 80fo of the water of the glomerular filtrate is
reabsorbed as the fluid flows through the proximal tubule.
The proximal tubule actively secretes waste products such
as hippuric acid, paraaminohippuric acid, choline,
guani-
dine and histamine from the interstitial fluid around the
tubule into the filtrate. From the proximal tubule the
filtrate flows into the loop of Henle (which is mainly in
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the medulla). In the descending limb water diffuses out
of the loop of Henle by countercurrent distribution. By
the time the filtrate reaches the bend of the loop it is
greatly hypertonic. The ascending limb is impermeable
to water- Chloride is actively transported out and sodium
follows passively. The filtrate leaving the loop is again
isotonic but the volume is now reduced to approximately
l/o of the original glomerular filtrate.
In the distal tubule further volume reduction and
acidification occur. Acid-base balance is primarily
+ + +
regulated by the active secretion of H , K and NH-^ in
this portion of the tubule. Several other solutes, e.-g. :
salts and some organic acids, are reabsorbed during passage
of the filtrate through the distal tubule. The tubules
converge into the collecting duct where the tonicity of
urine is determined by the level of vasopressin controlled
water reabsorption. Finally all the collecting ducts unite
in the pelvis and form the ureter v/hich transports the
urine to the bladder.
3. Cyclic AMP and the Kidney
The neurohypophyseal hormone vasopressin, which is
also called antidiuretic hormone (ADH), enhances the perme
ability of a number of epithelial membranes to water,
sodium and small molecules. This action is particularly
important in regulating the osmolality of urine in the
collecting ducts. Vasopressin is secreted by the
hypo-
11
thalamus in response to a hypertonic plasma. Orloff and
Handler (1967) found that, like many other hormones, vaso
pressin uses cAMP as its secondary messenger. ADH stimu
lates adenyl cyclase, in cell walls of collecting ducts and
distal tubules, to produce cAMP. The cAMP increases cell
membrane permeability to H^O which enhances reabsorption
of water out of the tubules. Jost and Rickenburg (1971)
noted that cAMP makes membranes of the distal tubule and
+
loop of Henle more permeable to Na . Thus through the
action of vasopressin, the body can conserve both.Na and
water.
4. The Renin-Angiotensin-Aldosterone System
Aldosterone is a steroid hormone, produced in the
adrenals , that fosters the reabsorption of Na and
+ +
excretion of K and H from the distal tubule (Rao, 197-1)
Renin, a proteolytic enzyme, is released from the juxta
medullary cells of the kidney in response to decreased
plasma volume, arterial pressure or renal blood flow.
Renin hydrolyzes a plasma protein called angiotensinogen
to form angiotensin I. Angiotensin I is converted to angio
tensin II by a "converting enzyme". Angiotensin II is
the most potent hypertensive agent known. Angiotensin II
stimulates the secretion of aldosterone. The sum total
of the action of renin, angiotensin, and aldosterone is
balanced retention of NaCl, production of an anti-diuretic
12
action, and an increase in blood pressure (Crouch and
McClintic, 1971).
Thus the kidney has two systems (the vasopressin
system and the renin system), responding to different stim
uli, that are responsible for water and electrolyte balance.
D Djj^rss is_ , Diuretics
1 Definition
Diuresis is an increase in the rate of production
of urine. It can be induced by: excessive fluid intake,
alcohol, some drugs (diuretics) and some disease states
(e.g. diabetes insipidus, diabetes melitus and pregnancy).
2. Modes of Diuresis Induction
Diuretics. may increase urine formation In seven ways
(Rao, 1971. Hutcheon, 1967)
a. Inhibition of chloride ion reabsorption and therefore
water reabsorption, e.g. by ethacrynic acid.
b. Increase in renal filtration rate, i.e. blood flow
increase with heart stimulants, e.g. by methyl xanthines.
c. Inhibition of passive reabsorption of sodium by decrease
in membrane permeability, e.g. by mercurial diuretics.
d. Induction of tubular fluid hyperosmolality, for example
by ingestion of salts that are not totally reabsorbed,
e.g. by mannitol and NagSOj,.
e. Carbonic anhydrase inhibition producing Inhibition of
H+,
Na+
exchange and therefore retention of Na and its
osmotic water in the tubule, e.g. by thiazides.
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f . Antagonism or blockage of aldosterone action, e.g. by
triamterine and spironolactone.
g. Change in tubule fluid composition without change in
total electrolyte composition, e.g. by NRYC1.
3. Structures and Classes of Diuretics
a) Osmotic Diuretics
Osmotic diuretics are either nonelectrolytes like
mannitol and urea, or
electrolytes'
like Wa^SO^, and KCI.
They are short acting, as they are excreted rapidly in
the urine. They are used in cases of acute brain swelling
and oliguria, and never with cardiac edemas. (Rao, 1971)
b) Acid Forming Salts
The only acid forming salt commonly used is ammonium
chloride. In the body the ammonium ion is converted to
urea and hydrogen ion. The hydrogen ion reacts with the
body buffers, including the bicarbonate ion, which ends
up as C0?. Thus the extracellular fluid composition is
changed without changing the total electrolyte concentra
tion. Because of this the kidney receives a large amount
of chloride, much of which escapes reabsorption, along with
an equal amount of sodium, and an iso-osmotic volume of
H20. Because of the acidosis that results from the hydro
gen ion production, the kidney must reestablish acid-base
balance. This is carried out by excretion of H and
ammonia instead of sodium. When balance is re-established,
as much ammonium chloride as administered is excreted, and
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the continued effect of the diuretic is lost. These diuretics
are used when response to other diuretics produce metabolic
alkalosis (Rao, 1971 and Hutcheon, 1967).
c) Mercurial Diuretics
The effects of all mercurial diuretics on the kidneys
are almost alike. The basic structure of the useful
1 2 3 1
mercurial diuretics is: R CH2CH(0R }HgR , R may vary
2 3
greatly, R is generally a methyl group, and R .is often
a methyl xanthine. The diuretic action is thought to be
due to in vivo intrarenal hydrolysis of the carbon-mercury
2+
bond releasing a free Hg m the proximal tubule . Even
2+
a small amount of Hg inhibits the reabsorption of Cl
and the Na and v/ater that v/ould follow it. In addition
2+ +
Hg depresses proximal tubule secretion of K into the
filtrate. But this depression is overcompensated by the
+ + +
greater availability of Na for Na -K exchange in the
distal tubule . One result of mercurial diuretic therapy
is a slight loss of H into the filtrate (Burg and Green,
2+
1973a). Side effects of Hg include: hypochloremic
alkalosis, flushing, dermatitis, nausea, gastrointestinal
irritation and extracellular depletion of electrolytes.
If used in indiscriminate and/or frequent doses, systemic
mercury poisoning can occur. Mercurial diuretics are used
in: cardiac edema, nephritis, nephrotic syndrome, ascites







primary mode of action is to increase heart function which
increases glomerular filtration rate. In addition these
diuretics increase proximal tubular solute reabsorption.
They are primarily used in cases of cardiac decompensation,
and impaired circulation. Their use is limited because their
effect diminishes with continued use.
e) Ethacrynic Acid,
HO2CMtC0
forms a cysteine-ethacrynic acid complex and this complex
inhibits active reabsorption of chloride in the thick
ascending limb of the loop of Henle and absorption of
sodium in the proximal tubule (Burg and Green, 19?3"b) .
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Abramow (19?4) found that ethacrynic acid is an antagonist
of vasopressin at the hormone receptor site in the collect
ing duct. It is a very potent diuretic used in problems
such as: acute pulmonary edema, congestive heart failure
and in hepatic and liver diseases that result in fluid
retention. Adverse effects include: hypokalemia, meta
bolic alkalosis, uremia, and hyperuricemia. Metabolic
alkalosis is thought to be due to loss o: excessive





like ethacrynic acid, primarily acts in the thick ascending
limb of the loop of Henle where it inhibits active chloride
reabsorption, (Burg et al., 1973)- Unlike ethacrynic acid,
it does not produce metabolic alkalosis because it Inhibits
carbonic anhydrase. This inhibition results in excessive
bicarbonate excretion, which counteracts excessive chloride
excretion. Adverse effects include: prerenal azotemia,
hypokalemia, hyperuricemia, and electrolyte imbalance. It






acts on the thick ascending limb of the loop of Henle where
it reportedly inhibits active chloride reabsorption and
*
passive sodium reabsorption (Puschett and Steinmuller,
1972). It produces phosphaturia, presumably by also inhib
iting phosphate reabsorption in the proximal tubule . One
of the major benefits of using this diuretic to treat edema
is that it does not cause hypokalemia. This diuretic Is
used in severe edema, but like ethacrynic acid and furo
semide, it is not used in mild edemas. Its major adverse
effects are: hyperuricemia, hypophosphatemia and metabolic
alkalosis (Rao. 1971).
h) Spironolactone , Aldosterone Antagonist
Aldosterone antagonists compete for aldosterone binding
sites in the distal tubule and thus prevent the action of
aldosterone which is to increase the reabsorption of Ka ,C1
+ +
and an i so-osmotic quantity of v/ater, and to increase Na -K
exchange rates. Evidence for this mode of action Is that
aldosterone antagonists are only effective when aldosterone
is actively secreted (Rao, 1971). Hyperkalemia does not become
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severe because more aldosterone is released as serum K
rises in response to the drug.
Spironolactone ,
SOCCH3
is the only diuretic of this kind currently on the market.
It is generally used in conjunction with diuretics that
are proximal tubular inhibitors to treat edemas that are
otherwise uncontrollable.!
i) Triamterene, an Aldosterone Blocking Agent
+ +
This class of diuretics inhibits Na -K exchange
across the distal tubular cells by direct inhibition of
the enzymes responsible for changing membrane permeability
(Rao, 1971). The result of their action is the failure to
reabsorb Na , thus causing diuresis by tubular fluid
hyper-
osmolality. These diuretics may induce hypokalemia because
their action is independent of the level of aldosterone and
thus these drugs are not as therapeutically safe as aldo
sterone antagonists . The currently available diuretics of









These diuretics are usually used in conjunction with a
proximal tubular inhibitor to treat resistant edemas (Rao,
1971).
j ) Thiazides
This group of diuretics has the following structure:
^R-R
WaN02.
Chlorothiazide, the most frequently used diuretic in this
group, has R-L=C1, and R2=^' Potency of the thiazides
depends on the R groups . The pharmacological mode of action
is reported to be by inhibition of
Cl~
reabsorption in the
thick portion of the ascending loop of Henle. Some thiazides
are potential proximal tubular carbonic anhydrase inhibitors .
Thus this class of diuretics may have two separate sites
20
of action in the kidney cortex, the ascending limb of the
loop of Henle and the proximal tubule . Thiazides are
therapeutically useful in cases of chronic cardiac decom
pensation, hepatic, renal and premenstrual edemas, and
toxemia of pregnancy. In addition they are used in con
junction with other drugs to treat hypertension. Adverse
effects include: hyperuricemia, mild hyperglycemia,




Antihypertensive drugs are compounds that reduce
high blood pressure (hypertension) . They are used in
cases that have diastolic pressures chronically above
105 mm Hg or acutely above 120 mm Hg.
2.Modes of Action
Antihypertensives act in one of seven ways (AMA, 1973)
a. Direct smooth muscle relaxtion e.g. by hydralazine,
sodium nitroprusside and diazoxide.
b. Blockage of beta-adrenergic receptor sites e.g. by
propranolol .
c. Blockage of alpha-adrenergic receptor sites e.g. by
phentolamine and phentolamine mesylate.
d. Depression of sympathetic activity and depletion of
catecholomine stores in the sympathetic nerve terminal
by reserpine, methyl dopa and guanethidine sulfate.
e. Blockcade of autonomic ganglia e.g. by mecamylamine
hydrochloride and trimethaphan comsylate .
f . Inhibition of monoamine oxidase e.g. by pargyline
21
hydrochloride.
g. Extracellular volume depletion and creation of negative
Na balance e.g. by thiazides.
3 . Classes of Antihypertensives
Propranolol and hydralazine were the only antihyper
tensives used in this research that were not discussed
under diuretics and consequently will be the only com
pounds discussed here in detail.
a) Direct. Smooth Muscle Relaxants
These drugs act by directly causing relaxation of
arteriolar smooth muscle. Diazoxide and sodium nitro-
prusside are used only during episodes of acute hyperten
sion. These drugs depress hypertension within two minutes
when injected i.v. Nausea, rapid heart beat, muscular
twitching, etc. are observed side effects with these drugs
Hydralazine,
MHMH-
is given orally for management of chronic hypertension
and i.v- during crises. Because it sustains (or increases)
renal blood flow, it is particularly useful in renal hyper
tension. Side effects observed with administration of this
drug include: headache, rapid heart beat, palpitations,
and gastrointestinal disturbances. Prolonged use in high
doses (above 200 mg/day) can cause acute rheumatoid syndrome
(fever, severe joint pain and swelling, enlarged spleen,
and fluid retention), (AMA, 1973).
b) Beta-adrenergic, Blocking Agents
A beta-adrenergic receptor is a site where epinephrine
binds after it is released from the adrenals or the sympa
thetic nervous system. When epinephrine binds at heart
muscle receptors it causes heart rate to increase, when it .
binds at receptors In vascular smooth muscle it causes
muscle relaxation.
A beta-adrenergic blocking agent is believed to act
by blocking the beta-receptor sites in the heart, thereby
inducing a reduction in heart rate and cardiac output,
(AMA, 1973). The only therapeutically utilized beta-
adrenergic blocking agent is propranolol,
OC^CHCHjNHCH ( CH^
OH
Propranolol is the only known beta blocking agent that is
not also intrinsically a stimulator when it binds at the
receptor site (Clarkson, 1975) It is prescribed for
hypertensive patients v/ith angina; and it is administered,
with hydralazine plus a diuretic, to chronic hypertensive
patients who cannot tolerate other combinations of anti
hypertensives. Side effects observed v/ith propranolol
therapy include: gastrointestinal disturbances, mental
depression, fatigue and insomnia.
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c) Alpha-adrenergic Blocking Agents
An alpha-adrenergic receptor is a site in vascular
smooth muscle where norepinephrine binds after it is
released from the sympathetic nervous system. ;Jhen nore
pinephrine binds to the receptor site it causes muscle
contraction.
Alpha-adrenergic blocking agents are believed to act
by blocking the alpha-receptor sites in sooth muscle,
thereby reducing vasoconstriction. These drugs are useful
only in hypertension caused by an excess of circulating
catecholamines hypertension caused by pheochromocytoma.
Orthostatic hypertension, nausea, rapid beating of the
heart, etc. are observed side effects with these drugs.
(AMA., 1973).
d) Depletors of Catecholamine Stores
The antihypertensive effect of these compounds has been
attributed to the depletion of catecholamine stores in the
sympathetic nerve synapses. Reflex nerve impulses to
arteries and arterioles are only partially inhibited by
catecholamine depletion, therefore blood pressure can be
reduced without creating severe hypotension. These drugs
are administered orally for chronic hypertension. They
may be administered i.v. during acute hypertensive crises.
Mental depression, bradycardia diarrhea, etc. are observed
side effects with these drugs (AMA, 1973)-
e) Ganglionic Blocking Agents
24
These drugs, which partially inhibit all peripheral
nerve function are administered only in severe hypertensive
crises, e.g. acute aortic aneuryisms , when immediate blood
pressure decrease is required. Side effects experienced
with ganglionic blocking agents include: urine retention,
nausea, loss of appetite, lens paralysis, etc. (AMA, 1973)-
f) Monoamine Oxidase Inhibitors
The mode of action of this class of antihypertensives
is poorly understood, but is believed to be through the
production of a false transmitter which Induces vasodilation
and reduction in cardiac output. These drugs are used in
cases of chronic hypertension that do not respond to other
antihypertensives. Psychosis, insomnia, nausea, etc. are
observed side effects with these drugs (AMA, 1973).
g) Thiazides
The diuretic thiazides are also mild antihypertensive
agents. They decrease extracellular volume and cause
+
negative Na balance. These drugs may also act by directly
inducing vascular smooth muscle contraction. Thiazides are
used alone in treating mild hypertension and as part of a
drug combination in treating moderate to severe hypertension
(AMA, 1973).
4 . Combination Diuretic and Antihypertensive Agent Therapy
Some antihypertensive agents, e.g. pargyline hydro
chloride, reserpine and mecamylamine hydrochloride, Induce
Na and water retention, and weight gain. Diuretics, e.g.
2'
furosemide, ethacrynic acid and triameterene are administered
in combination v/ith these antihypertensives, to control these
drug induced retentions. Combinations of diuretics and
antihypertensives are also used in treatment of hypertension
associated v/ith spontaneous fluid retention e.g. acute




Hypertension is defined as any condition which results
in high blood pressure- It is difficult to pick a dividing
line betv/een normal and high blood pressure, because in
sampling large populations, one smooth frequency distribu
tion curve results (Beever et al., 1975). One night expect
a two humped curve indicating the normal and abnormal popu
lations. In the management of hypertension, the dividing
line between hypertension and normotension has been arbitrar
ily set at 110 mm Hg diastolic pressure (Beever et al. , 1975)
2 . Classification
Hypertension can be divided into two basic types.
Essential hypertension (EH) is hypertension with no known
cause; 70-90/5 of all cases of hypertension fall into this
category. Secondary hypertension can be divided into 5 sub
classes.: 1) failure of the kidney (renal hypertension),
2) adrenal cortical overstimulation, 3) adrenal medullary
malfunction, 4) coarctation (narrowing or compression) of
the aorta and 5) pregnancy. Kinds of renal hypertension
include: renal vascular disease, glomerular nephritis,
pyelonephritis, polycystic kidney and collagen disease.




syndrome and congenital adrenal hyperplasia. The only
known cause of adrenal medullary hypertension is
phaeo-
chromocytoma .
3 . Spontaneous Hypertension (SH) in Rats and Essential
Hypertension (EH)
~
Since study of hypertension in humans is difficult,
most investigators use rats as models. By twenty generations
of inbreeding of VJistar rats v/ith high blood pressure, a
strain has been developed that is spontaneously hyperten
sive (Okamato, 1972). SH appears in about 85? of rats of
this strain by age eight weeks. SH in rats is considered
the best available model for EH pathology in humans. Both
SH and EH are considered to have genetically controlled
components in their etiology (Okamato, 1972; Hansen, 1972;
and Tanase, e_t al. , 1972).
a) Effects on the Body
As hypertension (SH) develops, kidney and vascular
tissue degenerate and become sclerotic; the heart hyper
trophies; blood vessel walls thicken; blood pressure
gradually rises; ocular damage occurs; the endocrine system
overfunctions , and vascular brain damage occurs. If untreated,
death may result from cerebral hemorrhage, renal failure,
2 7
arteriosclerosis or heart failure -
"b) Metabolic Abnormalities of SH Rats
Four basic areas have been targets of study: cate
cholamine metabolism, cardiac function and metabolism,
endocrine organs and the kidney.
1 ) Catecholamine Metabolism
Since the most effective antihypertensive drugs act
by diminishing vascular adrenergic, activity, investigators
began their investigations by looking for abnormalities
in catecholamine metabolism as causes or results of SH.
Sjoerdema (1972) measured norepinephrine In various
tissues and found lower than normal levels in the brainstem,
spleen, heart and kidney of SH rats. He suggested that this.
indicated decreased peripheral sympathetic activity that is
secondary to SH. Nagatsu et al. (.1972) studied the enzymes
involved in biosynthesis of catecholamines and found: 1) nor
mal tyrosine hydroxylase activity in the brain, heart and
spleen; 2) low tyrosine hydroxylase activity In the brain
stem; 3) elevated tyrosine hydroxylase and dopamines-hydroxy
lase activities in the adrenals; and 4) low DOFA decarboxylase
activity in the brainstem. From these results they concluded
that: 1) changes in enzyme activity exist in SK rats, and
2) increased adrenal catecholamine synthesis may have a
modulating effect on tyrosine hydroxylase activity in other
tissues .
Ozaki et al. (1972). found that development of hyper-
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tension followed increase of catecholamine content in the
adrenal gland and greater adrenergic sensitivity of the SH
brain to dopamine. Vetadyokoska et al. (1972) reported:
1) an increased unbound pool of norepinephrine, but decreased
total norepinephrine; 2) a decreased turnover of norepine
phrine; and 3) an increased reactivity of alpha-adrenergic
receptors. They concluded that the decreased norepinephrine
turnover, a biochemical correlate of decreased sympathetic
activity, may be an attempt to compensate for an increased
peripheral resistance resulting from vascular changes .
Tanaka (1972) attributed the low activity of DOPA decarboxy
lase in brain tissue to the low activity of extraneural
decarboxylase. Nagatsu (1976) found increased dopamine
beta-hydroxylase activity in the adrenal and messenteric
vessels and lower activity in the locus ceruleus of the SH
brain.
In summary, there are changes in catecholamine metabo
lism but they appear to be secondary to hypertension and
are attempts to compensate for it.
2) Cardiac Function and Metabolism
Initial cardiac studies were aimed at determining the
cause of increased vascular resistance in SH rats. Two
possible. causes were suggested: 1) increased vascular
reactivity to norepinephrine; and 2) hypertrophy of blood
vessel walls. Vascular reactivity is vasoconstriction in
response to catecholamines. Folkow et al. (1972) found that
2?
vascular walls thickened early in the development of SH
but that luminal size is unaltered. Shibata (1972) found
that there is a difference in vascular reactivity that was
missed in earlier experiments because tv/o components in
vascular reactivity exist, a fast one and a slow one. The
fast one is the same in normal and SH rats, but in SH rats
the slow response is absent. He also found that the
4-4*
availability of Ca may play an important role in the
mechanisms leading to the differences in vascular reacti
vity between SH and normotensive rats. This role may be
that Ca , which is a necessary cofactor for contraction
in all muscle, is not available for slower response. In
SH sarcoplasmic reticulum, high calcium dependent ATPase
activity and low calcium binding capacity were noted. Aoki
(1972) suggested that the muscle relaxing ability may be
reduced in the heart muscle of SH rats .
Fujiwara et al. (1972) found that SH cardiac atria
developed spontaneous tension higher than normal rats as
a compensatory mechanism to maintain a constant blood
supply to peripheral vessels with high resistance. Takatsu
and Kashii (1972) found marked cardiac hypertrophy in SH
rats both on a macroscopic and microscopic level. Micro
scopically, myocardial cells increased in size, the
mito-
chrondria and sarcoplasmic reticulum increased in size,
and the ratio between mitochrondria. and myofibrils decreased
Macroscopically, heart size increased and vessel walls
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thickened. In SH they found higher than normal activity
of most of the enzymes related to energy metabolism.
Amer (1973) found that SH rat aortas, contain lower
Intracellular cAMP levels and higher pdase activity, es
pecially the lower K form. Adenyl cyclase specific
activity was normal but less than normally responsive
to hormonal stimulation. The lower cAMP level may lead to
greater tension in blood vessels. ,
These kinds of vascular and cardiac changes are asso
ciated with greatly Increased susceptibility in SH rats to
cerebrovascular problems such as: intracerebral infarct,
intracerebral hemorrhage, subarachnoidal hemorrhage,
fibrinoid necrosis and atherosclerosis.
In summary, vascular changes in SH rats include increased
adrenergic reactivity and hypertrophy. A single enzyme could
be responsible for these changes, if the abnormal enzyme
e.g. pdase could diminish the ability of the SH vascular
system to respond to hormonal regulation mediated by cAMP.
3) Endocrine Glands
Hyperfunction of endocrine glands could be , at least
in part, a primary cause of SH in rats. Tsuchiyama et al.
(1972) studied the adrenals of SH rats and found structural
and enzymatic alterations suggesting hyperfunction. Tabei
et al. (1972) studied the pituitary, adrenals, thyroid and
hypothalamus of SH rats and found all these glands were
hyperfunctioning .
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The pituitary secreted excess TSH, ACTH and vasopressin.
Production and storage of lipids and catecholamines by the
adrenals was increased. The thyroids secreted excess thy
roid hormone probably due to excessive TSH stimulation.
Hypothalamic secretion of oxytocin and vasopressin, for
storage and release by the posterior pituitary, was increasd.
Because all these changes were already present in infant
SH rats In the prehypertensive state, they surmised that
endocrine hyperfunction may be part of the pathogenesis
, of hypertension. Since cyclic AMP is the intracellular
messenger for many .of the hormones, abnormalities in its
metabolism could be responsible, in part, for the hyper
function.
4) The Kidney
Biochemical abnormalities in the kidney were suspected
as a possible cause of SH, because malfunctions of the kid
ney are responsible for other forms of hypertension.
Kolet-
sky and Shook (1972) established that the abnormality v/as
not in the renin-angiotensin system since it was not hyper
active but v/as hypoactive. Therefore the renin-angiotensin
system abnormality in the kidney is probably not causing
hypertension, but the kidney may be attempting to partially
compensate for hypertension by diminished renin release.
Preuss et al. (1974) discovered an increase in oxygen
consumption and para-aminohippurate transport in SH rats.
The significance of this is unknown. Forcelli et al. (1975)
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found that kallikrein excretion in SH rats is considerably
decreased. Whether the abnormality is in the production or
release of kallikrein is unknown, and so is its relation
to high blood pressure. Baer et al. (1972) determined that
sodium balance has no apparent role in the pathogenesis
of SH. However, when SH is developed in these rats, Farman
and Bonvalet (1975) showed that the Na excretion response
to a high salt load is markedly impaired. They surmised
that this defect is due to a difference in tubular (possibly
distal) reabsorption of Ka , which could be due to impaired
function of the distal tubule, or abnormally high mineral
-
ocorticoid secretion. The defect could be due to abnormal
cyclic AMP concentration, since cyclic AMP effects perme
ability of membranes to sodium.
Ogino et al. (1972) found a substance in normal rat
kidneys that, if injected, into normal rats, produces tem
porary hypertension. The substance was extracted from
the kidneys of normal adrenalectomized rats. If injected Into
SH rats, it produces even greater blood pressure elevations.
It was not renin, but otherwise its identity is unknown.
Its role, if any, in the pathogenesis of SH is unknown.
Using parabiotic connections between normal and. SH rats,
Ebihara (1972) established that SH cannot be transmitted
to normal rats through the blood, so the abnormality is
not a free-circulating compound. Unlike adenyl cyclase
activities in aortic tissues, mentioned earlier, adenyl
3
cyclase activities have been found to be elevated in SH rat
kidneys (Chandar, 1976).
In summary, some of the abnormalities which exist in
SH rat kidneys are definitely secondary to hypertension,
and others exist which could be part of the primary path
ogenesis of SH.
c) Treatment
Treatment in man and rat is the same. One or more
diuretics such as chlorothiazide along with antihyperten
sives such as: reserpine, hydralazine, and propranolol
are administered as soon as a pathogenically critical
elevation in blood pressure is detected.
Hamilton (1975). Kohler (1975) and Freis (1972) reported
that if treatment of SH rats is started early enough it can
prevent blood pressure elevation in rats of SH strain. The
antihypertensives and diuretics prevent the hypertrophies,
arteriosclerosis, and other damaging effects of SH as long
as treatment is continued. If treatment is started too late,
blood pressure is lowered but the other effects are not re
versed. It then appears that these drugs effect the basic
SH mechanisms or their cumulative effects, since treatment
begun early totally blocks development of any of the symptoms
of SH. It is possible that these drugs are direct antagon
ists of the basic -mechanism of the pathogenesis of SH and EH.
G . Cyclic AMP Phosphodiesterase
1. Properties
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Most cAMP pdases have pH optima between pH 7-0-8.0
(Cheung, 1967; and Shroeder and Rickenbert, 1973). Some
pdases are stable at for several months (Cheung, 1970;
Drummond and Perrot-Yee, 1961; and Thompson and Williams, 1972).
Pdases have been partially isolated from several tissues.
Estimates of molecular weight vary from 40,000-300,000 (Cheung,
1971; Jaro and Bernard, 1971; Bergstand and Lundquist, 1976;
and Shroeder and Rickenberg, 1973 ) Tota? purification
results in loss of between 80-90^ of the activity of pdase
(Bergstand and Lundquist, 1976; Cheung, 1971; and Goren and
Rosen, 1972) . This may be due to loss of pdase activator
proteins during purification. The variations in molecular
weight and kinetic properties (Table I), may be due to 1)
variance with tissue source, 2) loss of activator proteins
and 3) the existance of multiple forms of pdase (Bergstand
and Lundquist, 1976; Goren and Rose, 1972; Beavo et al. , 1971;
and Thompson and Appleman, 1971).
Bergstand and Lundquist (1976) and Thompson and Appleman




and cAMP but that others are specific for one substrate or
the other. Thompson and Appleman (1971) found evidence for
at least two forms of pdase in every tissue they studied.
2- Location in Cells
Ultracentrifugation of cell homogenates can separate
cytoplasmic (supernatant), microsomal, mitochondrial, cell
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Table I. Selected Rm Values in Mammialian Tissues








Rat Kidney Cortex 0.075mM
















Goren and Rosen (1972)
Goren and Rosen (1972)
Beavo et al. (1970)
Honda and Imaura (1968)
Honda and Imaura (1968)
Garst et al. (1976)
Garst et al . (1976)
Eismaif Snd Martin (1976)
Eisman and Martin (1976)
Brooker (1972)
Brooker (1972)
Thompson and Appleman (1971)
Thompson and Appleman (1971)
Thompson and Appleman (1971)
Thompson and Appleman (1971)
Thompson and Appleman (1971)
Thompson and Appleman (1971)
Thompson and Appleman (1971)
Jaro and Bernard (1970)
Jaro and Bernard (1970)
Bergstand and Lundquist (1976)
Bergstand and Lundquist (1976)
Bergstand and Lundquist (1976)
Nair (1966)
All reaction pH's were between pH 7.0
- 8.0
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wall, membrane and nuclear fractions. Butcher and Sutherland
(1962) found kOf'n of the pdase activity of beef heart homo
genates in the supernatant fraction after 2000 X g centri
fugation. Nair (1966) found dog. heart pdase distributed
57;-- in the cytoplasm, k0f> in the nuclei and membranes,
2% in the microsomes and
If'
in the mitochondria. Rat
cerebral cortex pdase is distributed 33/= in the mitochon
dria, 36$ in the cytoplasm, 21; S in the microsomes and 5/*
in membranes and nuclei (DeRobertis et al. , 1966). Campbell
and Oliver (1972) found tissue specific distributions in
the rat (Table II). Rat kidney pdase, according to Eisen
and Martin (1976) , is distributed predominantly In the
cytoplasm, 62"'), and membranes,
35-'-'
Repeated homogenizing
released almost all of the pdase activity into the super
natant. The authors speculated that all of the pdase may
be membrane bound in vivo . Assuming that their speculation
is correct, their results are consistent with those of Camp
bell and Oliver.
In summary, the pdase of all tissues, except brain, may




Our working hypothesis has been that some diuretics
act by altering cAMP pdase activity and thereby modulating
cAMP concentrations and tissue responses to hormones. The
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Table II. Percent of Total Tissue Pdase in Subcellular
Fractions (Campbell and Oliver, 1972).
Tissue Membrane Mitochondria Microsomes 100,000 X g
Supernatant
Brain 6 33 10 51
Liver 11 5 10 74
Spleen 5 4 4 87
Kidney 4 9 10 78
Heart 23 9 15 53
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first reported inhibitions of pdase by diuretics were by
methyl xanthines (Butcher and Sutherland, 1962). There have
been scattered additional reports of other diuretics that
inhibit pdases, Table III. Amer et al. (1972) reported that
the potent diuretics chlorothiazide and 1- L(tert-butylimino)
methyl] -2-(3-indolyl)indolineCMJ-8592-l] were specific inhib
itors of kidney pdase. Senft ei; al. (1968) reported that
furosemide and hydrochlorothiazide inhibilted renal pdase
in vitro and in vivo. The in vivo studies were done by
administration of the diuretic i.v. , and then the pdase
levels of extracts of separated portions of the kidney v/ere
measured in vitro. The effect of the injection of the
compounds was to decrease pdase activity in the regions of
-
the kidney believed to be the physiological sites of action
of the diuretics. Furosemide decreased pda.se activity only
in the cortex where the thick ascending limb of the loop of
Henle is located; hydrochlorothiazide decreased pdase activity
only in the medulla. Amer et al. (1972) also reported
that theophylline was not a selective pdase inhibitor, but
inhibited pdase in the brain, heart and kidney.
Two questions were the starting point for this research.
Do diuretics effect kidney pdase activities of SH and NH rats
differently; Do diuretics effect pdase activities of kidney
cortex and medulla differently?
b) Non-diuretics
Numerous pharmacologically active compounds have been
;,o
Table III. Diuretics Reported to Inhibit cAMP pdase.
Iq.5 is the concentration reported to inhibit 50%.
Compound Enzyme Source 10.5 (mM) Reference
Acetazoleamide Cat heart 0.1 Weinryb et al. (1972)
Acetazoleamide Rat brain 1.0 Weinryb et al. (1972)
Acetazoleamide Rat kidney 0.4 Senft et al. (1968)
Bendroflumethiazide Cat heart 0.1 Weinryb et al. (1972)
Bendroflumethiazide Rat brain 0.1 Weinryb et al. (1972)
Caffeine Dog heart 0.5 Nair, (1966)
Caffeine Rat brain 0.3 Cheung (1967)
Chlorothalidone Rat kidney 2.5 Senft et al. (1972)
Chlorothiazide Rat kidney
- Senft et al. (1972)
Ethacrynic Acid Rat Kidney 0.4 Senft et al. (1972)
Furosemide Cat brain 0.1 Weinryb et al. (1972)
Furosemide Rat brain 0.3 Weinryb et al. (1972)
Furosemide Rat kidney
- Senft et al. (1968)
Theophylline Beef heart 0.1 Butcher and Sutherland (1962)
Theophylline Rabbit brain 0.1 Honda and Imaura (1962)
Theophylline Rat kidney 4.2,8.1 Jaro and Bernard (1970)
Chlorathiazide Rat kidney 2.9 Amer et al. (1972)
MJ-8592-1 Rat kidney 3.4 Amer et al. (1972)
Theophylline Rat kidney 1.3 Amer et al. (1972)
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reported to inhibit cAMP pdase (Table IV). The variety of
pharmacological activities involved reflect cAMP's role as
a "secondary
hormone"
for several different hormones.
^ Assays for Cyclic AMP Phosphodiesterase
All methods of measuring cyclic AMP pdase levels have
the following in common:
i The buffer is Tris.HCl or imidazole
ii Optimal pH is between 7 and 3
iii Mg is a cofactor
iv The substrate is cAMP
The original method of measuring cAMP pdase activity
used exogenous
5'
-nucleotidase to convert product 5 '-AMP
to adenosine and phosphate (Butcher and Sutherland, 1962).
Released inorganic phosphate was measured colormetrically .
The main disadvantage of this procedure is that It is. very
insensitive (minimum substrate concentration is 1 X
10"
'M) ,
The paper chromographic technique of Cheung (1976b) and
Mandel and Kuehl (1967) utilized ^H-cAMP substrate, paper
chromographic separation of cAMP and
5'
-AMP, and quanti
tation of cAMP, and
5'
-AMP by liquid scintillation counting
This method is very sensitive (minimum substrate concentra-
tion is about 10 'M), bux lengthy (2-3 days are needed to
complete an assay) , and requires 30-40 scintillation vials
per reaction. Brooker (1972) used high pressure liquid
chromotography v/ith ultraviolet absorption quantitation
of the Li product in pdase reactions. This method is lees
41

















Dihydroergotarrlne Fat cells ^-adrenergic
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Antiallergic Roy and VJarren (1974)
Dopan! ne Heart Adrenergic
Receptor
Goren and Rosen (1972b)
Impipramine Fat cells Lipolysis Schv/abe et al. (1972)
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Kefenamic acid Cartilage Anti-inflamatory Kev-'combe et al. (1974)
Nicotinamide
Nicotinic acid
Liver - Shimoyama et al. (1972)




Tranzuilizers Honda and Imaura
(1963)
Furorrycin ihuscle Antibiotic Appleman and 'hemp (1974)
Pyrazolones Cartilaere Anti - inf lamatory Dev.-combe et al. (1974)







sensitive than the paper chromotographic technique (min
imum substrate and product quantities are 10~^M) but faster
(an assay can be Completed in one day) . Eisman and Martin
(1976) used neutral alumina columns to separate
J
P labelled
pdase substrates and products. The minimum substrate con
centration is about 1 X 10~12M, but the cost of -^2P~cAMP and
the radiation energy of
J
"P limits the usefulness of the
procedure to analyses requiring maximum, sen-sitivity .
A kinetic modification of the radioisotopic technique
of Brooker et al. (1963) was adapted for this research
(see methods). In the basic method, excess exogenous
5'
-nucleotidase is added to the pdase reaction mixture to
convert all
5'
-AMP (the pdase reaction product) formed to
uncharged adenosine. The reaction solution is then mixed
v/ith anion exchange resin in a liquid scintillation vial
to stop the reaction and bind the ionic substrate to the
resin. After a binding equilibration period, an organic
scintillation fluid is added and the radioactivity in
uncharged organic soluble reaction products is measured in
a liquid scintillation counter. Beta particles released by
radioactive substrate bound to the resin do not reach the
scintillation fluid and are therefore not counted. Only
3 3
^H-adenosine and any ^H-cAMF on the resin surface are
quan-
titated. The -^H-cAMP on the resin surface Is accounted for
by using a blank containing everything except pdase. This
method Is the fastest, requires the fewest scintillation
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vials, and has a substrate concentration lower limit of
-9
10 li. Two variations of this method have been suggested:
1) Anion exchange columns have been used to separate
substrate from products (Filburn and Karn, 1973)
2) The addition of ethanol is reported to decrease
the binding of adenosine and increase the binding
of cAMP to the resin (Londesborough, 1976).
In summary, the fastest, most commonly used, and econ
omically most practical pdase assay is the anion exchange
resin method of Brooker et al. (1968) which v/e have adapted
to a kinetic method by collecting several samples during the
reaction period.
hU
II MATERIALS AND METHODS
A. Materials'.
Materials used in the experiments were obtained from
the following sources: Theophylline, cAMP, 5!-AMP, imida
zole and snake venom
5'
-nucleotidase , Sigma Chemical Com
pany; AG l-x2 200-400 mesh and AG l-x2 100-200 mesh anion
exchange resins, Bio-Rad Laboratories; cAMP- H(G) and
Omnifluor, New England Nuclear; metolazone, triamterene,
quinethazone , chlorothiazide, ethacrynic acid, furosemide
and spironolactone, Pennwalt Corporation. Pairs of normo
tensive and spontaneously hypertensive rats were gifts from
the Pharmaceutical Division of Pennwalt Corporation; and
Sprague-Dawley rats from the R.I.T. colony of rats. All
other chemicals were reagent grade or better. Liquid scin
tillation fluid was 1:1 EGME: toluene with Omnifluor (4g/l).
B. Methods:
1. Preparation of Tissue Extracts
Each rat was anesthesized v/ith ether. The kidneys
v/ere removed and chilled in
0"
50 mM imidazole buffer,
pH=7-0. All subsequent steps were performed at 0-4.
After dissection, each tissue was homogenized in one volume
of buffer with a Ten Broeck homogenizer- The homogenate
was centrifuged at 15,000 rpm (27.000 X g) in a Sorvali
RC2B Superspeed centrifuge in a 33-34 rotor. The supernatant
v/as diluted to produce 20-30>S product in the enzyme react.! -n
45
after 20 minutes. The reactions were started, not more than
one hour after the removal of the kidney from the rat , by
the addition of supernatant to buffered substrate.
2. Preparation of Scintillation Yials
Clean dry glass scintillation viais were immersed in
57/o dichlorodimethylsilane in benzene at
60**
, dried and
rerinsed. Silylation of the vials did not alter the scin
tillation counting efficiency but it reduced the binding of
the anion exchange resin to the galss and made the vials
easier to clean. If the resin adheres to the walls of the
vial sporadic counting rates are observed. Six ml of
scintillation fluid were placed in each vial and the vial
v/as counted 1 minute on the Beckman LS-250 liquid scin
tillation counter to estimate the
vials'
backg:round radio
activity. The fluid was removed and saved for reuse- The
vials were rerinsed, dried and approximately 0-5 ml of anion
exchange resin was added to each vial. No resin was placed
in the control vials that were used to determine the 100$
substrate radioactivity cpm value. One half ml of redis
tilled water v/as added to each vial to moisten the resin
so that it rapidly mixed with added reaction mixture.
3 Cyclic AMP Phosphodiesterase Analytical Method
The procedure used v/as a modification of the method
of Brooker et al. (1963). Each reaction mixture contained
50 mM imidazole, 50 rr ihg(0Ac)2> 2.2 X
10~5
M cAMP (2 X
10'
cpm %-cAMP), pH 7.0 in 500^1, 100 jul 5* -nucleotidase
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(0.6 mg/ml), and 200 /xl H^O or drug solution. Each reaction
was started by addition of 300 jul of tissue extract. At pre
set times, 100 jul aliquots of the final mixture were added
to. separate resin containing vials. Two 100 pl aliquots
were removed and added to vials containing no resin. After
15 minutes of equilibration between the resin -and the aliquot,
18 ml of scintillation fluid was added. After a 1.5 hour
dark adaptation period in the liquid scintillation counter,
the radioactivity in each vial was counted for five minutes.
*
A repeat count on all vials v/as subsequently performed.
4. Calculations
The cpm data and reaction times were converted to
reaction rates (cpm/min) using a least squares computer
program. The rates were converted to enzyme specific
activities (nmoles cAMP hydrolized per min per mg protein)
by:.
slope (cpm/min)
;'i product per min= n s /. ->..? , . u >
control cpm (100^o substrate)





Specific activities of control versus drug containing reac
tions were compared to obtain
;"'
inhibitions by the drugs.
Analyses were routinely done in triplicate.
5 . Procedure for Regeneration of Anion Exchange Resin
The used resin was collected in a Buchner funnel, rir-'jed
with 1 liter acetone, 1 liter water and 1 liter 17. KaCH.
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The alkaline resin v/as rinsed with water until the rinsings
were neutral. The neutral resin was washed v/ith IK HC1, and
then rinsed with H?0 to neutrality. One half ml of moist
resin was counted. If the cpm was less than 1000 cpm the
resin was ready for reuse; if it was not, the rinsing
procedure v/as repeated until the cpm value was 1000 or lower.
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IV RESULTS AND DISCUSSION
A Development of Kinetic Fdase Assay in Procedure
Since one of the objectives of this work was to study
the kinetic properties of kidney pdase, it was necessary
to 'modify the method of Brooker et al. (1963), 'see Methods).
Product formation versus time studies v/ere performed to
check the linearity. of the reaction with time. The reaction
v/as linear for at least 20 and for substrate con
version of up to 30$ product (Figure 4). Linearity was
evaluated using a least squares computer program. The
usual criterion was a correlation coefficient greater than
O.960 for the slope to be considered a reliable rate deter
mination. Only one sample at each time interval v/as utilized
in routine analyses. Single time rate determinations
were initially not reliable in our hands .
B. Kinetic Parameter Determinations
Dependence of reaction rate on substrate concentrations
-6 -2
between 1.0 X 10 M and 2.0 X 10 M v/as analyzed using homo
genate supernatant of whole Sprague-Dawley rat kidneys . Each
portion of the concentration range was run twice, using four
different rats. Four sets of experimental data were normal
ized in order to determine the shape of rats vs substrate
concentration response of kidney pdase (Figure 5)
This plot indicated that pdase has at least two active
binding sites, each with its own set of kinetic parameter:-.;
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or that more than one form of enzyme exists. The enzyme
does not appear to follow Michaelis-Menton Kinetics, so
each kinetic parameter was designated as a half-saturation
constant, (S)0 ,- rather than Km. The two empirical (S)Q /s
-5 -3
are 1.5 X 10
J
M, and 1.0 X 10
J
M, and their respective
-Q / /






moles/min/mg protein. The lower (S)Q ^ is the
one of physiological interest because it is near the phys
iological concentration of cAMP.
C . Specific and Total Activities of Separated Medulla and Cortex
Two cyclic AMP concentrations v/ere chosen - one just
below the lower (S)n ^ , and one above the higher (S)n r ;
such that rate measurements would maximally represent the
separate (S)0 * characteristics rather than major contri
butions from both catalytic reactions.
Four kidneys were dissected into cortex and medulla,
and each part weighed to determine percent weight of each
fraction (Table V). The specific activity of the medulla
Is 2-3 times greater than that of the cortex. The total
activity of the cortex, because it is 91% of the kidney
-2
weight, is 81/S of the total kidney pdase activity at 10
'
M
cyclic AMP and ?4 at
10--5
M (Table V). The relative
specific activity at the two cAMP concentrations is about
ten-fold apart for each tissue (cortex, medulla, and whole
kidney) . Therefore we assume that the pdases of the cortex
and medulla both have dependence of rate on substrate con-
cr4
Table V. Kinetic Study of Separated Kidney Corte^ and ihedulla Pdase
"from Sprague-Dav/ley Rats
React Ion times v/ere: 0,3 >7i 14,21 minutes























Ranges on f weights are: for cortex - 37-95/' and for medulla -
5-13;"
Specific Activity ic in moles/rnin/ng protein
Relative total activity is specific activity X /j grams of tissue
100 grams of kidney
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centration similiar to that of the whole kidney. (Figure 5).
D. Surveys of the Interactions of Diuretics with Pdase of
Whole Rat Kidney
Three concentrations of each drug were used to deter
mine If the pdase sensitivity to each drug was concentration
dependent. Metolazone and chlorothiazide both inhibited
pdase slightly at all 3 concentrations (Table VI). The
dependence of the effect on dring concentration was not
clear cut in either case. Ethacrynic acid, quinethazone,
theophylline and triamterene all ihibited significantly
and the first three appear to cause Increasing inhibition
with increased drug concentration (Table VII). The observed
pdase inhibitions by all five different classes of
tested are consistent with our original hypothesis that a
common mode. of action of diuretics may be by interaction
v/ith pdases in kidney.
E. Mode of pdase Inhibition by Drugs
These experiments were designed to determine if the
Inhibition by drugs follows first order kinetics. Theo
phylline and ethacrynic acid concentrations v/ere varied
over a fifty-fold range and data were plotted as l/rate
versus inhibitor concentration (Figures 6 & 7)- To a first
approximation the inhibitions follow first order kinetics
and for ethacrynic acid a common half saturation level nay
exist at both substrate levels.
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Table VI. Study to Determine the Effects of the Diuretics
Metolazone and Chlorothiazide on the Phosphodi
esterase Reaction.
Specific activity for control
= 2.23 X moles
per minute Der millie:ram_protein.
CCyclic AMP] = 9.0 X 10 ^7.
Reaction times = 0; 3. 7.14,21 minutes
Drug Drug (nl:) Pdase
Reaction
Rate (CPM/sec)
Corr- Coef. f> Inhib .
K 0.00 1.30 0 . 932 0
7-
0.08 1.19 0.992 9
n.T
0.16 1.15 0 . 939 12
vT
0.31 1.10 0.939 16




C 1-55 0.38 0 . 995 31





'able VII. Study to Determine the Effects of Four Additional
Diuretics on the Phosphodiesterase Reaction .




moles per minute per milligram protein.
[Cyclic yf} = 9.0 "X 10"-5 I,
Reaction times = 0,3,7,3.4,21 minutes
Drug Drug (mM) Pdase
Reaction
Rate (CPM/sec)
Corr. Coef. f Inhib.
N 0.00 1.76 0.936 0
E 0.35 1 . 74 0 . 997 1
E 0.70 1.30 0.9^2 26
E 1.39 0.90 0 - 99-4 49
w 0.00 1.33 0 . 994 0
Q 0.56 1.60 0.999 13
Q- 1.12 1.61 0.999 13
Q 2.23 1.20 0.933 34
'
f,-
0.00 1 . 85 0 . 99t* 0
0.56 0.85 0.935 54
TH 1.12 .0.56 O ooo 70




T 0.05 1.45 0.99? 20
T 0.09 1.31 0 . 993 2S
T 0.13 1..34 0.993 26
N = Mono T - Triamterene
E = Ethacrynic Acid
Q Quine thazone "heophylline
Figure 6 . 1/rate vs ^Theophylline]]
CcAMPJ = 0.09 mM
Sprague-Dawley whole kidney homogenate v/as used.
Sampling Times = 0,3.7>l4, and 21 minutes
Drug levels = 1.12, O.56, 0.28, 0.l4, and 0.07 ml
Figure 7* i/slo-oe vs [Ethacrynic Acid}
CcAMP] = 0.09 mM and 0.45 mM
Sprague-Dawley whole kidney homogenate was used.
Sampling Times = 0, 3.7.14 and 21 minutes
Drug Levels = 2.00, 1.00, 0-50, 0-30, 0.25,
0.13, 0.. 07 mM.
5
1/rate vs Ctheophyll i ne]
T
.015
Inh ibitor (mM x1 0 )
60












F . Comparison Studies between Cortex and Whole Kidney
This study v/as performed to determine if the specific
activity and inhibition characteristics of cortex pdase is
different from those of whole kidney pdase, and if any
factor from the medulla affects whole kidney reaction rates
observed in vitro. Within experimental error, the specific
activities of the cortex and the whole kidney are the same.
The inhibition of pdase by theophylline an| triamterene is
the same in the cortex and whole kidney homogenate (Table
VIII). The experimental value for the ethacrynic acid -
cortex analyses is not consistant with later values, see
Table IX. Since the cortex has approximately 85^ of the
total activity of the kidney, it was expected that unless
there was some needed cofactor from the medulla, specific
activity and inhibition characteristics would be the same
In both tissues. It v/as concluded that no cofactor exists
In the medulla that changes the in vitro analyses of either
pdase activity or diuretic Inhibition characteristics of
the cortex enzyme .
G - Comparison Study between Cortex and Medulla Pdase
This study v/as undertaken to compare the pdase specific
activity in the medulla and cortex of Sprague-Dawley rats,
and to determine if the diuretics theophylline and etha
crynic acid have any tissue specificity. No tissue speci
ficity with either diuretic was observed. (Table IX) The
earlier observation (Table V) that the pdase specific
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Table VIII Comparison of Vlhole Kidney and Cortex Pdase Activity
and Inhibition
Assays v/ere done in triplicate.
Sprague-Dawley whole kidney homogenate, and cortex
homogenate were from the same rat.
fcAMP]j= 9.0 X 10-5 ;.;
_^
Cethacrynic acid]
= 2.1 X 10
J
7 {theophylline) =3.1 X 10
(/triamterene) = 1.0 a 10-f- M [quinethazone] = 1.3 X 10~3 M
Sampling times - 0 , 3 , 7 , 14 , 21 minutes .
Precision values are standard deviation.
-3
Tissue Drug Average Specific Activity 0
( (mole/min/mg protein) X IO7) fi Activity





0.46 + 0.09 42 + 8
\\
Theophylline 0.32 + 0.07 30 + 7
11
Quinethazone 0.34 3
0.04 7? + 4
ti
Triamterene 0.64 + 0.03 59 i 3
Cortex None 1.21 + 0.15 100 + 12
?.
Etha 0.70 + 0.10 53 + 8
crynic Acid
.I
Theophylline 0.40 + 0.05 33 + 4
1
Quinethazone 0.76 + 0.07 63+6
n
Triamterene O.65 + 0.03 54+7
63
Table IX. Comparison of Cortex and Medulla, Pdase Activity and
"inhibition
Dissected Sprague-Dawley kidneys were used
All analyses v/ere performed in triplicate on the
same homogenate.
r
LcAMPl = 1.2 X 10
J
M.
theophylline] = 3-1 X 10
*
K.0
Dsthacrynic acioD = 2.1 X 10
J
M.
Sampling times = 0,3 , 7 ,14, 21 minutes
Precision values are standard deviation.







Cortex ?"one 0.76 + .01 100 + 1
Cortex Ethacrynic
Acid
0.34 + .11 45 t 15
Cortex Theophylline 0.15 + .05 19 + 6
Medulla Mone 1.73 + .12 100 t 7
Medulla Ethacrynic
Acid
0.78 + .11 44 + 6
Medulla Theophylline 0.33 + .02 21 + 1
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activity of the medulla extract is significantly higher than
that of the cortex v/as confirmed (Table IX). Specificity
was not expected with theophylline because it has no reported
specific site of action in the kidney, but with ethacrynic
acid, specificity was expected, because its site of action
has been reported to be in the thick ascending limb of the
loop of Kenle which is located primarily in the cortex.
Ferhaps specificity v/as not seen because ethacrynic acid
acts on parts of the thick ascending limb of the loop of
> Henle in both the medulla and cortex.
H. SH - MH Rat Fair Experiments - High Drug levels
These experiments v/ere undertaken to determine drug
specificity for cortex and medulla, drug specificity
for cortex and medulla, drug specificity for SH or NH rats
and SH - NH specific activity differences. Six pairs (litter
mates) of rats from the Pennwalt Corporation v/ere used. The
rats v/ere all VJistar white rats. The blood pressure ranges
for the MH litter mate was 130-150 mm Hg systolic. The
blood pressure range for the SH litter mate was 190-300 mm
Hg systolic. The age range was 8-10 weeks. All rats v/ere
males. Kine drugs were studied, two antihypertensive com
pounds and 7 diuretics.
The medullary specific activities of both SH and 727
rats were double the cortical specific activity (Table X).
The KK rat cortex appeared to have slightly higher pdase
specific activity than the SH rat. cortex; the medullary
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Table X. Comparison of MH and SH Rats Specific Activities.
Six pairs of Mistar litter mates were used.
All analyses v/ere done in triplicate.
CcA.p] = 1.1 X 10-5 ih.
Sampling times = 4,8,12,16,20 minutes.










o^ec . Ac o .
2.26 + 0.37 2.11 + 0.44 0.9
Cortex.
Spec. Act.







< 1 indicates lower specific activity In SH rat
M/Ol indicates higher specific activity in medulla
a,c see key of Table XI
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pdase appears to have the same specific activity In the
litter mates. Two of the 6 paired rats had S/N values of
greater than one .
Since pdase specific activity in the SH rat appears
to be the same or lower than that of MH rats , and adenyl
cyclase specific activities are elevated (Chandar, 1976),
cAMP levels in SH kidneys must be elevated. This elevation
could be a metabolic compensation for edema resulting from
hypertension.
Both antihypertensives and all diuretics studied,
except spironolactone, inhibited pdase activity in vitro ;
spironolactone activated cortex pdase in vitro (Table XI) .
Some drugs appeared to act differentially in medulla and
cortex and differentially in NH vs SH rat homogenates .
Several statistically significant specificities observed
should be noted. Spironolactone activated the cortex
enzyme but not the medulla enzyme from both NH and SK rats .
Hydralazine and propranolol preferentially inhibited the
cortex enzyme of both MH and SH rats and they appeared to
have less ability to inhibit the SH enzyme of each tissue
compared to the NH rat enzymes .
Furosemide- v/as the strongest pdase inhibitor tested at
3-.0 X 10
J
M drug concentrations. It clearly inhibited the
medullary enzyme more than the cortex enzyme of both types
of rats and the MTH enzyme more than the SK enzyme of both
tissues .
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Table XI . f Activities of Pdase in Presence of Dru/rs for Kidney
Medulla and Cortex Extracts from SK and NH Rats .
All were v/hite male VJistar rats aged 3-10 weeks
Six -nairs of litter mates were used
rcAKP} = 1.1 X 10-5 k
Sampling times were 4.3,12,16,20 minutes
! = Medulla extract. C = Cortex extract.
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Furosemide ( .0 mM) Chlorothiazide (3.0 mi.) Quinethazone (1.3 rcM)

























Ethacrynic Acid (3.0 mM) Triamterene (0.1 mM)

































Table XI. f Activities in Presence of Drugs (cont'd)
Key a.7>
oqa
confidence of being statistically different from 1.0
b"^ oyLi




" " " " " "
M/C"7l indicate relative drug specificity for cortex
M/C-^l indicate relative drug specificity for medulla
S/M
"*
1 indicate relative drug specificity for KHR
S/M<1 indicate relative drug specificity for SHR
* these values indicate relative drug specificity
for cortex because the drug activates the pdase of
the cortex selectively, rather than inhibiting the
pda.se of the medulla more specifically, as the values
appear to indicate.
o
Chlorothiazide and quinethazone appear to be more
effective in SH rat extracts than In NH rat extracts. Al
though ethacrynic acid and triamterene are pdase inhibitors,
tissue and rat specificaties were not establishable from the
available data.
Some of the difference's in specificities can be explained
in terms of the proposed physiological sites of action of
the drug. Spironolactone effects only the pdase of the
cortex, and its physiological site of action is the aldo
sterone system which is located solely in the cortex (Rao,
1971) Hydralazine and propranolol effect arteriolar vas
culature (AMA, 1973)i and the cortex has most of the arter
iolar vasculature; It follows that these drugs should have
their sites of action in the cortex.
Metolazone'
s pharma
cological site of action is the thick ascending limb of
the loop of Henle (Puschett and Steinmuller, 1972), which
is in- both the cortex and medulla; therefore it is reason
able that it v/ould inhibit pdase activity in both tissues.
The greater inhibition in the cortex indicates that the
cortical portion of the ascending limb may be the more
important site of action. In the case of chlorothiazide
and quinethazone, whose site of action is the ascending limb
of the loop of Henle, drug inhibition is seen in both tissues
as v/ould be expected. Since
furosemide'
s pharmocological
site of action is the thick ascending limb of the loop of
Henle, it follows that it would inhibit pdase in both tissues.
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The strikingly greater inhibition in the medulla indicates
that the medullary portion of the ascending limb may be the
more important site of action. It was expected that triam
terene, as in the SH rat, should be more effective in the
cortex; as the aldosterone system, its site of action, is
located there. Ethacrynic acid, whose pharmacological
site of action is reported to be the ascending limb of the
loop of Henle (Abramow, 1974), appears to be very effective
in both cortex and medulla.
In summary the site of pdase modulation by the drugs
tested and their site of pharmacological action generally
appear to be the same. This suggests that the mode of
action of some antihypertensives and diuretics Is pdase
modulation. The differences betv/een SH and NH rats may to
some extent reflect the effectiveness of the drug. Chloro
thiazide, triamterene and quinethazone, which are most
effective pdase inhibitors in SH rats, are commonly used to
treat fluid retention resulting from spontaneous hypertension.
It is interesting that spirolactone , the only drug to acti
vate pdase is reported to compete with the hormone aldoster
one for its binding site in vivo. In contrast, the other
drugs may modulate enzyme activity affected by hormones
but are not known to compete for hormone binding sites.
I . Effect of Drugs at Low Concentrations on SH Rat Kidney "Mjase
All nine compounds, previously studied, were used in
this study of one SK
rat extract, in order to estimate if
71
the previous drug concentrations were much higher than the
concentrations at v/hich they had half of their effectiveness
(Table XII). Hydralazine had no effect on the in vitro pdase
activity at 3 X 10
-^
M. Therefore to exert an in vivo effect
on pdase with the dilute drug concentration hydralazine
would have to be concentrated in the kidney. Triamterene
-6
was not an effective inhibitor at 10 Mi. This concentration
is about 100-fold below what would be expected v/hen an aver
age dose of 100 mg (AMA, 1976) Is distributed evenly through
the blood and 9-fold below the concentration if the drug
were distributed through all body fluids. The appreciable
-4
inhibition observed with 10 M triamterene may be inter
preted as an indication that the drug may inhibit kidney
pdase in vivo even without concentration in the kidney.
Spironolactone, chlorothiazide and furosemide had less pro
nounced but still definite effects at lowered- drug concentra
tions. This indicates that concentration of these drugs in
the kidney is not necessary for modulation of pdase by
these compounds. Furosemide still inhibited both the
cortex and medulla extracts but the tissue
specificity-
observed with 3 mM drug was not corroborated at 0.03 mM
drug levels. The slight specificity for effectiveness in
the cortex at low furosemide concentrations may be consid
ered consistant with the in vivo results of Senft et al.
(1963) who studied the in vivo effects of furosemide on
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at the 100-fold diluted drug concentration appears to be
spironolactone, because it activates kidney cortex pdase
20;:^ at 0.3 uM.
At the low concentrations of propranolol, metolazone,
quinethazone and ethacrynic acid, experimental and control
reaction rates v/ere the same within experimental error -
Presumably, in order for these drugs to be effective in
vivo inhibitors of kidney pdase the drug concentration in
the kidney must be greater than 3 X
10--3
M.
Assuming (1) that the kidney filtrate is initially
blood plasma, (2) that the total plasma volumes is 3-5
liters, (3) the plasma drug concentration is the concentra
tion to which kidney enzymes are exposed, (^) that following.
medication there is no delay in bioavailability of the drug
to the plasma space, (5) an average molecular weight, for
compounds studied, of 300 and (6) typical medication doses
of 100 mg (AMA) , one can estimate a general concentration
of the drugs without considering accumulation of the drug
in the kidney.
iqq mg
In Vivo Concentration of a drug - 3^
fftef" = '1 mI/:
The drugs which accumulate in kidney tissue, e.g. meto
lazone, will be more concentrated than 0.1 mM and drugs
that exhibit delayed bioavailability, e.g. spironolactone,
will have lower concentrations effecting kidney enzyme
activities. Based on the inhibition observed in Tables Xi
and XII and the drug concentrations used in vitro all of
7]7
the drugs except hydralazine and propranolol would appear
to be concentrated enough to effective modulators of kidney
pdase in vivo .
V. CONCLUSIONS
A . Kinetic Parameters of Kidney Pdase
It was demonstrated by a kinetic anion exchange resin
isotopic analysis that the pdase of rat kidney homogenates
is a complex of enzymes with at least two distinct saturation
characteristics. These saturations may be described by an
SQ
- of 1.5 X
10~-5
M and a Vmax of 3 X
IO"9
moles/min/mg
protein and an SQ , of IX
IO"3
M and a Vmax of 1.1 X
IO""*
moles/min/mg protein. Kidney pdase does not appear to
follow simple Michaelis-Menton kinetics because ths V versus
S curve is not a smooth hyperbolic curve for either satura
tion level.
B . Effects of Diuretics and Antihypertensives on Kidney Fdass
All diuretics and antihypertensives studied modulated
kidney pdase activity. Chlorothiazide, ethacrynic acid,
furosemide, hydrolazine, metolazone, propranolol, quinetha
zone, theophylline and triamterene inhibited kidney pdase.
Spironolactone activated pdase.
YJith the exception of hydralazine and propranolol, all
drugs studied modulated kidney pdase at concentrations
expected if an average dose of drug is distributed through
the entire plasma volume. For hydralazine and propranolol.
to effect kidney pdase, they v/ould have to be
concentrate':
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in the kidney. It is condluded that these data support
the hypothesis that some diuretics and antihypertensives
may act in vivo by altering cAMP pdase activity and thereby
modulating cAMP concentrations and tissue responses to hor
mones .
Some of the diuretics and antihypertensives studied
appear to have tissue specificities for the medulla or cor
tex corresponding to their proposed phys iolcfgical sites of
action.
C . Differences between SH and KH Kidney Pdase, and Cortex and
Medulla Pdase
The pdase specific activity of homogenates of renal
medulla was approximately twice that of the cortex for both
*
SH and NH rat tissues. In terms of total activity, medulla
activity made up approximately 20f of the kidney activity,
but the medulla represented approximately 9>j of the kidney
weight. The pdase specific activity of NH and SH medulla
homogenates was approximately the same, but the SH cortex
specific activity was approximately 15% lower than the NH
cortex specific activity. This data combined v/ith the
adenyl cyclase data of Chandar (1976) showing increased
adenyl cyclase levels in SH medulla and cortex, strongly
indicates that cAMP levels in the SK kidney may be higher
than in the NH kidney. Such elevations of cAMP concentration.
may be part of a physiological response
of the kidney to
correct for edemas resulting from spontaneous hypertension.
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This would be consistant with the hypothesis that some
diuretics and antihypertensives may act by modulating
kidney pdase levels. An explanation of the rat specificity
of the drugs is not obvious at this time.
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